Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190204116 | Oral cavity | LP | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 21/4623 | 49/18723 | 4.00e-03 | 2.59e-02 | 21 |
GO:00506911 | Oral cavity | LP | regulation of defense response to virus by host | 18/4623 | 41/18723 | 5.51e-03 | 3.33e-02 | 18 |
GO:00506881 | Oral cavity | LP | regulation of defense response to virus | 27/4623 | 69/18723 | 5.55e-03 | 3.35e-02 | 27 |
GO:0043433 | Oral cavity | LP | negative regulation of DNA-binding transcription factor activity | 61/4623 | 185/18723 | 6.68e-03 | 3.89e-02 | 61 |
GO:000268315 | Oral cavity | LP | negative regulation of immune system process | 130/4623 | 434/18723 | 6.70e-03 | 3.90e-02 | 130 |
GO:007190111 | Oral cavity | LP | negative regulation of protein serine/threonine kinase activity | 42/4623 | 120/18723 | 7.27e-03 | 4.06e-02 | 42 |
GO:000007911 | Oral cavity | LP | regulation of cyclin-dependent protein serine/threonine kinase activity | 34/4623 | 94/18723 | 8.52e-03 | 4.61e-02 | 34 |
GO:002261215 | Oral cavity | LP | gland morphogenesis | 41/4623 | 118/18723 | 9.09e-03 | 4.85e-02 | 41 |
GO:200123326 | Oral cavity | EOLP | regulation of apoptotic signaling pathway | 99/2218 | 356/18723 | 1.25e-16 | 1.25e-13 | 99 |
GO:007259425 | Oral cavity | EOLP | establishment of protein localization to organelle | 108/2218 | 422/18723 | 2.91e-15 | 1.45e-12 | 108 |
GO:190332026 | Oral cavity | EOLP | regulation of protein modification by small protein conjugation or removal | 73/2218 | 242/18723 | 1.41e-14 | 6.47e-12 | 73 |
GO:000989625 | Oral cavity | EOLP | positive regulation of catabolic process | 118/2218 | 492/18723 | 2.32e-14 | 9.26e-12 | 118 |
GO:003133125 | Oral cavity | EOLP | positive regulation of cellular catabolic process | 106/2218 | 427/18723 | 4.63e-14 | 1.63e-11 | 106 |
GO:005134826 | Oral cavity | EOLP | negative regulation of transferase activity | 75/2218 | 268/18723 | 4.48e-13 | 1.22e-10 | 75 |
GO:007093622 | Oral cavity | EOLP | protein K48-linked ubiquitination | 31/2218 | 65/18723 | 9.08e-13 | 2.27e-10 | 31 |
GO:004593625 | Oral cavity | EOLP | negative regulation of phosphate metabolic process | 105/2218 | 441/18723 | 1.05e-12 | 2.46e-10 | 105 |
GO:001056325 | Oral cavity | EOLP | negative regulation of phosphorus metabolic process | 105/2218 | 442/18723 | 1.22e-12 | 2.60e-10 | 105 |
GO:004232624 | Oral cavity | EOLP | negative regulation of phosphorylation | 94/2218 | 385/18723 | 3.58e-12 | 7.15e-10 | 94 |
GO:003139626 | Oral cavity | EOLP | regulation of protein ubiquitination | 62/2218 | 210/18723 | 3.86e-12 | 7.34e-10 | 62 |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0465718 | Cervix | CC | IL-17 signaling pathway | 31/1267 | 94/8465 | 8.71e-06 | 7.43e-05 | 4.39e-05 | 31 |
hsa046686 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0465719 | Cervix | CC | IL-17 signaling pathway | 31/1267 | 94/8465 | 8.71e-06 | 7.43e-05 | 4.39e-05 | 31 |
hsa0466813 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa0465722 | Cervix | HSIL_HPV | IL-17 signaling pathway | 15/459 | 94/8465 | 1.45e-04 | 1.74e-03 | 1.40e-03 | 15 |
hsa0516923 | Cervix | HSIL_HPV | Epstein-Barr virus infection | 22/459 | 202/8465 | 1.35e-03 | 9.68e-03 | 7.82e-03 | 22 |
hsa0465732 | Cervix | HSIL_HPV | IL-17 signaling pathway | 15/459 | 94/8465 | 1.45e-04 | 1.74e-03 | 1.40e-03 | 15 |
hsa0516933 | Cervix | HSIL_HPV | Epstein-Barr virus infection | 22/459 | 202/8465 | 1.35e-03 | 9.68e-03 | 7.82e-03 | 22 |
hsa0516942 | Cervix | N_HPV | Epstein-Barr virus infection | 19/349 | 202/8465 | 6.54e-04 | 4.94e-03 | 3.86e-03 | 19 |
hsa0516952 | Cervix | N_HPV | Epstein-Barr virus infection | 19/349 | 202/8465 | 6.54e-04 | 4.94e-03 | 3.86e-03 | 19 |
hsa0516924 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa05169111 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa0516925 | Endometrium | EEC | Epstein-Barr virus infection | 47/1237 | 202/8465 | 6.17e-04 | 4.41e-03 | 3.29e-03 | 47 |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0465720 | Endometrium | EEC | IL-17 signaling pathway | 23/1237 | 94/8465 | 7.61e-03 | 3.63e-02 | 2.71e-02 | 23 |
hsa0516934 | Endometrium | EEC | Epstein-Barr virus infection | 47/1237 | 202/8465 | 6.17e-04 | 4.41e-03 | 3.29e-03 | 47 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNFAIP3 | SNV | Missense_Mutation | | c.36N>C | p.Leu12Phe | p.L12F | P21580 | protein_coding | tolerated(0.29) | benign(0.2) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
TNFAIP3 | SNV | Missense_Mutation | | c.1439N>A | p.Ser480Asn | p.S480N | P21580 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
TNFAIP3 | SNV | Missense_Mutation | | c.979N>T | p.Ala327Ser | p.A327S | P21580 | protein_coding | tolerated(0.07) | benign(0.305) | TCGA-A2-A0YG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TNFAIP3 | SNV | Missense_Mutation | | c.650N>C | p.Ser217Thr | p.S217T | P21580 | protein_coding | deleterious(0.01) | possibly_damaging(0.79) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TNFAIP3 | SNV | Missense_Mutation | | c.1711N>A | p.Val571Ile | p.V571I | P21580 | protein_coding | tolerated(0.48) | benign(0) | TCGA-BH-A0H6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNFAIP3 | deletion | Frame_Shift_Del | novel | c.285_294delNNNNNNNNNN | p.Lys96ValfsTer24 | p.K96Vfs*24 | P21580 | protein_coding | | | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TNFAIP3 | insertion | Frame_Shift_Ins | novel | c.2184_2185insACATTAGT | p.Ser729ThrfsTer90 | p.S729Tfs*90 | P21580 | protein_coding | | | TCGA-AR-A0TW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | PD |
TNFAIP3 | SNV | Missense_Mutation | rs775850329 | c.259N>G | p.Arg87Gly | p.R87G | P21580 | protein_coding | deleterious(0.03) | benign(0.009) | TCGA-C5-A2M2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TNFAIP3 | SNV | Missense_Mutation | | c.2193N>T | p.Glu731Asp | p.E731D | P21580 | protein_coding | tolerated(0.67) | benign(0.031) | TCGA-DS-A7WF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
TNFAIP3 | SNV | Missense_Mutation | novel | c.217N>G | p.Ile73Val | p.I73V | P21580 | protein_coding | tolerated(1) | benign(0) | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |